Good morning :)
$
₹
Glaukos Corp

Glaukos Corp

GKOS

NYSE
Asset Logo

Glaukos Corp

GKOS

NYSE
$163.591.34% (+2.17)
$
₹
$163.591.34% (+2.17)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Medical Devices

Mid Cap

With a market cap of $9.6B the stock is ranked 1000

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

14.83
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-3.27
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

1.64
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-30.69%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 15 analysts' reports

Buy
12 analysts
Hold
2 analysts
Sell
1 analyst

Analysts expect a +22.14% price upside over the next year

Current Price$163.59
Target Price$197.15

Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Peers

Peers

Abbott Laboratories
ABT
Abbott Laboratories
P/E Ratio
33.01
33.01
1Y Return
23.69%
23.69%
Buy Reco %
74.07
74.07
Danaher Corporation
DHR
Danaher Corporation
P/E Ratio
37.34
37.34
1Y Return
9.01%
9.01%
Buy Reco %
88.00
88.00
Intuitive Surgical Inc
ISRG
Intuitive Surgical Inc
P/E Ratio
43.29
43.29
1Y Return
11.99%
11.99%
Buy Reco %
66.66
66.66
Medtronic PLC
MDT
Medtronic PLC
P/E Ratio
23.09
23.09
1Y Return
2.88%
2.88%
Buy Reco %
53.12
53.12
Stryker Corporation
SYK
Stryker Corporation
P/E Ratio
29.14
29.14
1Y Return
27.02%
27.02%
Buy Reco %
68.75
68.75

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareMedical Devices

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Glaukos Corp -14.831.64
Abbott Laboratories33.013.451.87
Danaher Corporation37.342.791.25

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

133.5
-16.2
143.1
-133.6
150.5
-19.7
185.6
-18.3
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue85.6295.6996.67105.49106.66124.12133.53143.12150.57185.61
Net Income-40.83-50.54-21.40-33.58-18.14-19.65-16.23-133.65-19.78-18.37
Net Profit Margin-47.69%-52.82%-22.14%-31.82%-17.01%-15.83%-12.15%-93.38%-13.13%-9.90%
See CostsAll values in $ Million

Frequently asked questions

Frequently asked questions

  1. Glaukos Corp (GKOS) share price today is $163.59 as of September 19, 2026 at 1:30 AM IST. The stock touched a day high of $163.71 and a day low of $159.18.

  2. Glaukos Corp stock trades on NYSE under the ticker symbol GKOS.

  3. Glaukos Corp's market capitalization is $9.64B as of September 19, 2026 at 1:30 AM IST.

  4. Glaukos Corp's price-to-earnings (P/E) ratio is N/A as of September 18, 2026.

  5. Glaukos Corp's price-to-book (P/B) ratio is 14.83 as of September 18, 2026.

  6. Yes, You can buy Glaukos Corp shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Glaukos Corp shares in three steps: 1. Search Glaukos Corp on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Glaukos Corp trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Glaukos Corp (GKOS) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.0611 shares at the current price of $163.59.

Loading...